


"EXPRESS MAIL" LABEL NO. EL 625 570 835 US, Date of Deposit: February 13, 2002. I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

By


(Signature of person mailing)
ROY F. WALDRON

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: J. W. Coe et al.

: Examiner: Not Yet Assigned

SER. NO.: Not Yet Assigned

: Group Art Unit: Not Assigned

FILING DATE: Concurrently Herewith

:

TITLE: ARYL FUSED AZAPOLYCYCLIC
COMPOUNDS

:

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:


PRELIMINARY AMENDMENT

Prior to examination on the merits and calculation of filing fees, please enter the following amendments to the abstract, specification and claims. Marked up versions of the amendments to the abstract, specification and claims are found in the Appendix attached hereto.

IN THE ABSTRACT

at page 80, lines 7-12, delete the paragraph and insert the following new paragraph:

Compounds of the formula



and their pharmaceutically acceptable salts, wherein R¹, R², and R³ are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.

IN THE SPECIFICATION

at page 1, line 7, insert the following new paragraph:

This application is divisional application of U.S. Ser. No. 09/402,010, filed September 28, 1999, which is the National stage entry under 35 U.S.C. § 371 of PCT/IB98/01813, filed November 13, 1998 which claims the benefit of U.S. Provisional Application Ser. No. 60/070,245, filed December 31, 1997.

at page 1, lines 7-22, delete the existing paragraph and insert the following new one:

This invention relates to aryl fused azapolycyclic compounds, as defined more specifically by formula I below. Compounds of formula I bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function. Such compounds are useful in the treatment of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder, psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.

at page 3, lines 20-24, delete the existing paragraph and insert the following new one:

each R⁴, R⁵, R⁶, R⁷, R⁸ and R¹³ is selected, independently, from hydrogen and (C₁-C₆) alkyl, or R⁵ and R⁶, or R⁷ and R⁸ together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, -N-(C₁-C₆)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and


at page 5, after line 11, the following two new paragraphs are inserted:

Other embodiments of this invention relate to compounds of the formula I, and their pharmaceutically acceptable salts, wherein R² and R³ do not, together with the benzo ring of formula I, form a bicyclic or tricyclic ring system.

Other embodiments of this invention relate to compounds of the formula I wherein one or both of R² and R³ are -C(=O)R¹³, wherein R¹³ is (C₁-C₆)alkyl. Further embodiments of this invention relate to compounds of the formula I wherein one or both of R² and R³ are -C(=O)R¹³, wherein R¹³ is (C₁-C₆)alkyl or (C₁-C₃)alkyl optionally substituted with from one to seven fluorine atoms. Other embodiments relate to compounds of the formula I wherein one of R² and R³ is CF₃, fluoro, cyano or C₂F₅.

at page 7, after line 14, insert the following new paragraph:

The invention also relates to a compound of the formula



wherein R² and R³ are defined above; and P' is COOR¹⁶ wherein R¹⁶ is allyl, 2,2,2-trichloroethyl or (C₁-C₆)alkyl; -C(=O)NR⁵R⁶ wherein R⁵ and R⁶ are defined as in claim 2; -C(=O)H, -C(=O)(C₁-C₆)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, preferably with from 1 to 3 fluoro or chloro atoms; benzyl, or t-butoxycarbonyl (t-Boc).

at page 8, line 22 to page 9, line 19, delete the existing two paragraphs and insert the following two new ones:

The present invention also relates to a method of treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age

related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.

The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias , gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

at page 9, line 26 to page 10, line 8, delete the existing paragraph and insert the following new one:

The present invention also relates to a method for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's

Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of the formula

IN THE CLAIMS


Cancel claims 2, 3 and 11-14.

Add new claims 15-23 as set forth below.

Replace claims 1, 9 and 10 with the clean copies of the amended claims are set forth below. Marked-up versions of the amended claims may be found in the Appendix attached hereto.

CLEAN COPY- ENTER

1. (Once Amended) A compound of the formula



R¹ is hydrogen, (C₁-C₆)alkyl, unconjugated (C₃-C₆)alkenyl, XC(=O)R¹³, benzyl or -CH₂CH₂-O-(C₁-C₄)alkyl;

R² and R³ are selected, independently, from hydrogen, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, hydroxy, nitro, amino, halo, cyano, -SO_q(C₁-C₆)alkyl wherein q is zero, one or two, (C₁-C₆)alkylamino-, [(C₁-C₆)alkyl]₂amino-, -CO₂R⁴, -CONR⁵R⁶, -SO₂NR⁷R⁸, -C(=O)R¹³, -XC(=O)R¹³, aryl-(C₀-C₃)alkyl- or aryl-(C₀-C₃)alkyl-O-, wherein said aryl is selected from phenyl and naphthyl, heteroaryl-(C₀-C₃)alkyl- or heteroaryl-(C₀-C₃)alkyl-O-, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and X²(C₀-C₆)alkoxy-(C₀-C₆)alkyl-, wherein X² is absent or X² is (C₁-C₆)alkylamino- or [(C₁-C₆)alkyl]₂amino-, and wherein the (C₀-C₆)alkoxy-(C₀-C₆)alkyl- moiety of said X²(C₀-C₆)alkoxy-(C₀-C₆)alkyl- contains at least one carbon atom, and wherein from one to three of the carbon atoms of said (C₀-C₆)alkoxy-(C₀-C₆)alkyl- moiety may optionally be replaced by an oxygen, nitrogen or sulfur atom, with the proviso that any two such heteroatoms must be separated by at least two carbon atoms, and wherein any of the alkyl moieties of said (C₀-C₆)alkoxy-(C₀-C₆)alkyl- may be optionally

substituted with from two to seven fluorine atoms, and wherein one of the carbon atoms of each of the alkyl moieties of said aryl-(C₀-C₃)alkyl- and said heteroaryl-(C₀-C₃)alkyl- may optionally be replaced by an oxygen, nitrogen or sulfur atom, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to two substituents, independently selected from (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from two to seven fluorine atoms, halo, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, hydroxy, nitro, cyano, amino, (C₁-C₆)alkylamino-, [(C₁-C₆) alkyl]₂amino-, -CO₂R⁴, -CONR⁵R⁶, -SO₂NR⁷R⁸, -C(=O)R¹³ and -XC(=O)R¹³;

wherein each R⁴, R⁵, R⁶, R⁷, R⁸ and R¹³ is selected, independently, from hydrogen and (C₁-C₆) alkyl, or R⁵ and R⁶, or R⁷ and R⁸ together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, -N-(C₁-C₆)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and

each X is, independently, (C₁-C₆)alkylene;

with the proviso that: (a) at least one of R¹, R² and R³ must be the other than hydrogen, and (b) when R² and R³ are both hydrogen, R¹ cannot be hydrogen or methyl; and (c) both R² and R³ cannot both simultaneously be nitro.

9. (Once Amended) A pharmaceutical composition comprising an amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

10. (Once Amended) A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, [including] petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising

administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

15. (New) A compound according to claim 1 selected from the group consisting of 2-fluoro-N-(4-hydroxy-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-5-yl)-benzamide; 1-(10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-yl)-1-ethanone; and pharmaceutically acceptable salts thereof.

16. (New) A compound according to claim 1 selected from the group consisting of: 4-methyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-nitro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-amino-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; N¹-[10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-yl]acetamide; 4,5-difluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-chloro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 3-(10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-yl)-5-methyl-1,2,4-oxadiazole; 10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-ol; 4,5-dichloro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; N⁴,N⁴-dimethyl-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-sulfonamide; 4-(1-pyrrolidinylsulfonyl)-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 5-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-carbonitrile; 4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 5-ethynyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-carbonitrile; 5-chloro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-carbonitrile; 4-ethynyl-5-chloro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-chloro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-carbonitrile; 4-ethynyl-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4,5-bistrifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; and pharmaceutically acceptable salts thereof.

17. (New) A compound according to claim 6 selected from the group consisting of: 3-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;

3-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-yl cyanide;
4-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
and pharmaceutically acceptable salts thereof.

18. (New) A compound according to claim 1 that is:

4-nitro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

19. (New) A compound according to claim 1 that is:

4,5-dichloro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

20. (New) A compound according to claim 1 that is:

3-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

21. (New) A compound according to claim 1 that is:

3-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

22. (New) A compound according to claim 1 that is:

4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

23. (New) A compound according to claim 1 that is:

4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

REMARKS

Applicants have amended the Abstract to correct the description of the variables as presented in the structure. Applicants have inserted a statement on page 1 of the application to indicate the priority required by 37 C.F.R. § 1.78. Applicants have corrected a number of typographical and spelling errors on pages 1, 3, 7, 8 and 9, as specifically set forth above.

Applicants have inserted text on page 5 relating to other embodiments of the invention that are fully supported by claims 3-6 as originally filed. The insertion of the text at page 7 of the structure of formula (I') and accompanying description has full literal support in claim 14 in the application as originally filed. The insertion of "obsessive-compulsive disorder" at pages 8 and 9 and claim 10 into the lists of diseases, disorders or conditions for which pharmaceutical compositions comprising the compounds of the invention, and methods employing those compounds/compositions is supported by the description at page 1, line 18.

Applicants have amended claim 1 such that it relates only to compounds where R² and R³ do not join to form a ring and thus deletes the substituent list for R² and R³ where they form a ring. The Examiner will note that subject matter where R² and R³ form a ring is prosecuted in co-pending parent application, Ser. No. 09/402,010. This amendment has support in the specification at page 3, lines 7-19; and from page 4, line 8 to page 5, line 8. Applicants have amended the proviso (b) to clarify the scope of excluded compounds, and have also added a new proviso (c) to exclude species corresponding to intermediates. Consistent with this amendment to claim 1, Applicants have canceled dependent claims 2 which all relates to compounds where the groups R² and R³ do not together form a ring and now fall without the scope of amended claim 1. Applicants have canceled claim 3 as redundant of claim 1. Further, Applicants have canceled claims 11-14. Applicants have made these amendments and cancellations of claims without prejudice to file divisional application(s) drawn to the canceled subject matter.

Applicants have amended claim 9 to recite a pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier with the deletion of other descriptors in the claim. Applicants have amended claim 10 to correct several typographical, spelling and format errors.

New claims 15 through 23 set forth species corresponding to the invention. New claim 15 is supported by Examples 30 and 34. New claims 16-23 are supported by Examples 2, 3, 4, 5, 6, 7, 8, 9, 31, 32, 33, 35, 38, 39, 40 and 46 and the specification at page 6, lines 14 to 28.

All of the foregoing amendments have support in the application as filed. These amendments add no new matter to the application.

Applicants believe the present preliminary amendment renders the set of pending claims in condition for allowance and request the issuance of a Notice of Allowance. If a telephone interview would assist the furtherance of the prosecution of this application, the Examiner is invited to contact the undersigned.

Respectfully submitted,



Roy F. Waldron
Registration No. 42,208
Attorney for Applicant(s)

Date: 2/13/2002

Pfizer, Inc
Patent Department
150 East 42nd Street (150/05/49)
New York, NY 10017
(212) 733-5086

10030C-2534-021302


ATTACHMENT TO PRELIMINARY AMENDMENT

MARKED-UP VERSIONS OF AMENDED SPECIFICATION AND CLAIMS

IN THE ABSTRACT

at page 80, lines 7-12, delete the paragraph and insert the following new paragraph:

Compounds of the formula



and their pharmaceutically acceptable salts, wherein R¹, R², and R³ [and n] are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders [are claimed].

IN THE SPECIFICATION

at page 1, line 7, insert the following new paragraph:

This application is divisional application of U.S. Ser. No. 09/402,010, filed September 28, 1999, which is the National stage entry under 35 U.S.C. § 371 of PCT/IB98/01813, filed November 13, 1998 which claims the benefit of U.S. Provisional Application Ser. No. 60/070,245, filed December 31, 1997.

at page 1, lines 7-22, delete the existing paragraph and insert the following new one:

This invention relates to aryl fused azapolycyclic compounds, as defined more specifically by formula I below. Compounds of formula I bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function. Such compounds are useful in the treatment of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, [amyotrophic] amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac [arrhythmias] arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive [supramuscular] supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, [barbituates] barbiturates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder, psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.

at page 3, lines 20-24, delete the existing paragraph and insert the following new one:

each R⁴, R⁵, R⁶, R⁷, R⁸ and R¹³ is selected, independently, from hydrogen and (C₁-C₆)alkyl, or R⁵ and R⁶, or R⁷ and R⁸ together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, [piperazine, -N-(C₁-C₆)alkylpiperazine] piperazine, -N-(C₁-C₆)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and


at page 5, after line 11, the following two new paragraphs are inserted:

Other embodiments of this invention relate to compounds of the formula I, and their pharmaceutically acceptable salts, wherein R² and R³ do not, together with the benzo ring of formula I, form a bicyclic or tricyclic ring system.

Other embodiments of this invention relate to compounds of the formula I wherein one or both of R² and R³ are -C(=O)R¹³, wherein R¹³ is (C₁-C₆)alkyl. Further embodiments of this invention relate to compounds of the formula I wherein one or both of R² and R³ are -C(=O)R¹³, wherein R¹³ is (C₁-C₆)alkyl or (C₁-C₃)alkyl optionally substituted with from one to seven fluorine atoms. Other embodiments relate to compounds of the formula I wherein one of R² and R³ is CF₃, fluoro, cyano or C₂F₅.

at page 7, after line 14, insert the following new paragraph:

The invention also relates to a compound of the formula



wherein R² and R³ are defined above; and P' is COOR¹⁶ wherein R¹⁶ is allyl, 2,2,2-trichloroethyl or (C₁-C₆)alkyl; -C(=O)NR⁵R⁶ wherein R⁵ and R⁶ are defined as in claim 2; -C(=O)H, -C(=O)(C₁-C₆)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms, preferably with from 1 to 3 fluoro or chloro atoms; benzyl, or t-butoxycarbonyl (t-Boc). --

at page 8, line 22 to page 9, line 19, delete the existing two paragraphs and insert the following two new ones:

The present invention also relates to a method of treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, [amyotrophic] amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac [arrythmias] arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive [supramuscular] supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, [barbituates] barbiturates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a

mammal, comprising administering to a mammal in need of such treatment an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.

The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, [amyotrophic] amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac [arrhythmias] arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive [supramuscular] supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, [barbituates] barbiturates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising an amount of a compound of the formula I, or a pharmaceutically [acceptable] acceptable salt thereof, and a pharmaceutically acceptable carrier.

at page 9, line 26 to page 10, line 8, delete the existing paragraph and insert the following new one:

The present invention also relates to a method for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, [amyotrophic] amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac [arrhythmias] arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive [supramuscular] supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, [barbituates] barbiturates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of the formula


IN THE CLAIMS

Amend claim 1, 9 and 10.

Cancel claims 2, 3 and 11-14.

Add new claims 15-23.

1. (Once Amended) A compound of the formula



R¹ is hydrogen, (C₁-C₆)alkyl, unconjugated (C₃-C₆)alkenyl, XC(=O)R¹³, benzyl or -CH₂CH₂-O-(C₁-C₄)alkyl;

R² and R³ are selected, independently, from hydrogen, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, hydroxy, nitro, amino, halo, cyano, -SO_q(C₁-C₆)alkyl wherein q is zero, one or two, (C₁-C₆)alkylamino-, [(C₁-C₆)alkyl]₂amino-, -CO₂R⁴, -CONR⁵R⁶, -SO₂NR⁷R⁸, -C(=O)R¹³, -XC(=O)R¹³, aryl-(C₀-C₃)alkyl- or aryl-(C₀-C₃)alkyl-O-, wherein said aryl is selected from phenyl and naphthyl, heteroaryl-(C₀-C₃)alkyl- or heteroaryl-(C₀-C₃)alkyl-O-, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur, and X²(C₀-C₆)alkoxy-(C₀-C₆)alkyl-, wherein X² is absent or X² is (C₁-C₆)alkylamino- or [(C₁-C₆)alkyl]₂amino-, and wherein the (C₀-C₆)alkoxy-(C₀-C₆)alkyl- moiety of said X²(C₀-C₆)alkoxy-(C₀-C₆)alkyl- contains at least one carbon atom, and wherein from one to three of the carbon atoms of said (C₀-C₆)alkoxy-(C₀-C₆)alkyl- moiety may optionally be replaced by an oxygen, nitrogen or sulfur atom, with the proviso that any two such heteroatoms must be separated by at least two carbon atoms, and wherein any of the alkyl moieties of said (C₀-C₆)alkoxy-(C₀-C₆)alkyl- may be optionally substituted with from two to seven fluorine atoms, and wherein one of the carbon atoms of each of the alkyl moieties of said aryl-(C₀-C₃)alkyl- and said heteroaryl-(C₀-C₃)alkyl- may optionally be replaced by an oxygen, nitrogen or sulfur atom, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to two substituents, independently selected from (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from two to seven fluorine atoms, halo [~~e.g., chloro, fluoro, bromo or iodo~~], (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, hydroxy, nitro, cyano, amino, (C₁-C₆)alkylamino-, [(C₁-C₆) alkyl]₂amino-, -CO₂R⁴, -CONR⁵R⁶, -SO₂NR⁷R⁸, -C(=O)R¹³ and -XC(=O)R¹³;

[or R² and R³, together with the carbons to which they are attached, form a four to seven membered monocyclic, or ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the nonfused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents, preferably from zero to two substituents for the monocyclic rings and from zero to three substituents for the bicyclic rings, that are selected, independently, from (C₁-C₆) alkyl optionally substituted with from one to seven fluorine atoms, (C₁-C₆) alkoxy optionally substituted with from one to seven fluorine atoms, nitro, cyano, halo, (C₂-C₆) alkenyl, (C₂-C₆) alkynyl, hydroxy, amino, (C₁-C₆) alkylamino and [(C₁-C₆) alkyl]₂amino, -CO₂R⁴, CONR⁵R⁶, SO₂NR⁷R⁸, C(-O)R¹³ and XC(-O)R¹³;]

wherein each R⁴, R⁵, R⁶, R⁷, R⁸ and R¹³ is selected, independently, from hydrogen and (C₁-C₆) alkyl, or R⁵ and R⁶, or R⁷ and R⁸ together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, -N-(C₁-C₆)alkylpiperazine [piperazine, N-(C₁-C₆)alkylpiperazine] or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and

each X is, independently, (C₁-C₆) alkylene;

with the proviso that: (a) at least one of R¹, R² and R³ must be the other than hydrogen, and (b) when R² and R³ are both hydrogen, R¹ cannot be hydrogen [or methyl] (C₁-C₆) alkyl, or unconjugated (C₃-C₆) alkenyl; and (c) both R² and R³ cannot both simultaneously be nitro.

9. (Once Amended) A pharmaceutical composition [for treating a disorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD),

Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising an amount of a compound according to claim 1 [that is effective in treating such disorder or condition] and a pharmaceutically acceptable carrier.

10. (Once Amended) A method for treating a disorder or condition selected from inflammatory bowel disease , [~~including but not limited to~~] ulcerative colitis, pyoderma gangrenosum , [and] Crohn's disease [→], irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic [amytrope] lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac [arrhythmias] arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear [supramuscular] palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), [chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury (TBI),] psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, [including] petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

15. (New) A compound according to claim 1 selected from the group consisting of 2-fluoro-N-(4-hydroxy-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-5-yl)-benzamide; 1-(10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-yl)-1-ethanone; and pharmaceutically acceptable salts thereof.

16. (New) A compound according to claim 1 selected from the group consisting of: 4-methyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-nitro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-amino-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; N¹-[10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-yl]acetamide; 4,5-difluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; 4-chloro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;

3-(10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-yl)-5-methyl-1,2,4-oxadiazole;
10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-ol;
4,5-dichloro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
 N^4,N^4 -dimethyl-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-sulfonamide;
4-(1-pyrrolidinylsulfonyl)-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
5-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-carbonitrile;
4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
5-ethynyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-carbonitrile;
5-chloro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-carbonitrile;
4-ethynyl-5-chloro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
4-chloro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene-4-carbonitrile;
4-ethynyl-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
4,5-bistrifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
and pharmaceutically acceptable salts thereof.

17. (New) A compound according to claim 6 selected from the group consisting of:

3-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
4-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
3-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-trien-4-yl cyanide;
4-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene;
and pharmaceutically acceptable salts thereof.

18. (New) A compound according to claim 1 that is:

4-nitro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

19. (New) A compound according to claim 1 that is:

4,5-dichloro-10-azatricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

20. (New) A compound according to claim 1 that is:

3-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

21. (New) A compound according to claim 1 that is:

3-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

22. (New) A compound according to claim 1 that is:

4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.

23. (New) A compound according to claim 1 that is:

4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0^{2,7}]dodeca-2(7),3,5-triene; or a pharmaceutically acceptable salt thereof.